Manchester Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Manchester Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19K	Hold	400	–	–	﹤0.01%	686
2025 Q4	$21K	Hold	400	–	–	﹤0.01%	654
2025 Q3	$25.9K	Hold	400	–	–	﹤0.01%	700
2025 Q2	$19.5K	Sell	400 -600	-60%	-$23.2K	﹤0.01%	721
2025 Q1	$34K	Hold	1,000	–	–	﹤0.01%	621
2024 Q4	$39.4K	Hold	1,000	–	–	﹤0.01%	587
2024 Q3	$47K	Hold	1,000	–	–	0.01%	550
2024 Q2	$54K	Hold	1,000	–	–	0.01%	487
2024 Q1	$68.2K	Hold	1,000	–	–	0.01%	437
2023 Q4	$62.6K	Buy	+1,000	New	+$55.3K	0.01%	400
2022 Q1	–	Sell	-800	Closed	-$61K	–	1045
2021 Q4	$61K	Hold	800	–	–	0.01%	390
2021 Q3	$90K	Hold	800	–	–	0.01%	373
2021 Q2	$130K	Hold	800	–	–	0.02%	306
2021 Q1	$97K	Sell	800 -124	-13%	-$18.7K	0.01%	329
2020 Q4	$141K	Buy	+924	New	+$109K	0.02%	272
2019 Q2	–	Sell	-220	Closed	-$8K	–	570
2019 Q1	$8K	Buy	+220	New	+$7.61K	﹤0.01%	572

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Manchester Capital Management's CRSP Position: Q1 2026 in Review

Manchester Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 400 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #686.

Manchester Capital Management first reported a position in CRSP in Q1 2019 and has held it in 16 quarters since. The position peaked at $141K in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Manchester Capital Management held 400 shares of CRISPR Therapeutics worth $19K as of Q1 2026.
Manchester Capital Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #686 holding.
Manchester Capital Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 16 quarters since.
Manchester Capital Management's CRISPR Therapeutics position peaked at $141K in Q4 2020.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.